# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

<b>FORM</b>	8-K
-------------	-----

# **CURRENT REPORT**

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): September 3, 2025

# Oscar Health, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware (State or Other Jurisdiction of Incorporation) 001-40154 (Commission File Number) 46-1315570 (IRS Employer Identification No.)

75 Varick Street, 5th Floor New York, New York 10013 (Address of Principal Executive Offices) (Zip Code)

(646) 403-3677 (Registrant's telephone number, including area code)

Not Applicable (Former Name or Former Address, if Changed Since Last Report)

	ck the appropriate box below if the Form 8-K filing is intowing provisions:	ended to simultaneously satisfy the fil	ling obligation of the registrant under any of the		
	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)				
	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)				
	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))				
	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))				
Seci	urities registered pursuant to Section 12(b) of the Act:				
	Title of each class	Trading Symbol(s)	Name of each exchange		
Cl	ass A Common Stock, \$0.00001 par value per share	Trading Symbol(s) OSCR	Name of each exchange on which registered  New York Stock Exchange		
Indi	ass A Common Stock, \$0.00001 par value per	Symbol(s) OSCR growth company as defined in Rule 4	on which registered  New York Stock Exchange		
Indi cha <sub>l</sub>	ass A Common Stock, \$0.00001 par value per share cate by check mark whether the registrant is an emerging	Symbol(s) OSCR growth company as defined in Rule 4	on which registered  New York Stock Exchange		

#### Item 7.01. Regulation FD Disclosure.

Oscar Health, Inc. (the "Company") will participate in the 2025 Wells Fargo Healthcare Conference (the "Conference") on September 3, 2025. At the Conference, the Company will reaffirm the updated full year 2025 guidance that it provided in its preliminary financial results press release for the second quarter of 2025, dated July 22, 2025.

This information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in any such filing.

### **Cautionary Note Regarding Forward-Looking Statements**

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical fact contained herein are forward-looking statements. These statements include, but are not limited to, statements about our expected financial performance and upcoming events and presentations. Accordingly, we caution you that any such forward-looking statements are not guarantees of future performance and are subject to risks, assumptions, and uncertainties that are difficult to predict and generally beyond our control. Although management believes that the expectations reflected in these forward-looking statements are reasonable as of the date made, there are or will be important factors that could cause our actual results to differ materially from those indicated in these forward-looking statements, including, but not limited to, the factors set forth under the caption "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission ("SEC"), our Quarterly Report on Form 10-Q for the quarter ended June 30, 2025, and our other filings with the SEC. You are cautioned not to place undue reliance on any forward-looking statements made herein. Any forward-looking statement speaks only as of the date as of which it is made, and, except as otherwise required by law, we do not undertake any obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. New factors emerge from time to time, and it is not possible for us to predict which will arise.

# **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Oscar Health, Inc.

Date: September 3, 2025 By: /s/ R. Scott Blackley

R. Scott Blackley Chief Financial Officer